execut track maintain outperform
tender pay debt expect
save three year stabil
analyst certif import disclosur see
execut track maintain outperform
eyen report result provid busi updat indic us manag continu execut plan anticip
initi phase trial micropin progress myopia microprost intraocular hypertens glaucoma mid- late year
await updat next-gener optejet devic continu like eyen busi model target cash-pay custom
third-parti payer longer term believ may posit compani gener diversifi stream revenu
notabl commerci business-gener net revenu y/i oper incom vs year-
ago veru expect cash gener grow segment entir fund pipelin develop least end
earli initi clinic updat oral highli refractori prostat cancer support therapeut potenti challeng
tumor type nearest term look forward top-lin data zuclomiphen phase summer expect pave way
pivot us market opportun updat estim rais pt recommend entri risk-toler
investor ahead upcom newsflow
cloud
tender pay debt expect save three year stabil
pay billion per year debt save million increment expens per year three year million run
rate meaning given billion per year total think would also look buy-back asset sale
get close debt/ebitda ratio shift focu buyback stock yield dividend yield investor
confid pay debt see better growth stock stabil averag cost debt
around updat model reflect debt paydown
investor day highlight key tenet growth margin expans capit alloc outlin initi support long-term organ
growth bp annual om expans focal topic includ transform phase ii post spin pillar connected/digit suppli
chain growth product focus invest margin lever coalesc around iter enhanc data product vast oper
data intern better capture/collate/deploy continu optim footprint suppli chain growth mix strategi talent manag
view long-term articul driver underscor continu anyth given track record continu articul
improv yield tail around driver growth om expans affirm guidanc full year
